Navigation Links
Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
Date:9/30/2013

HOUSTON, Sept. 30, 2013 /PRNewswire/ -- Moleculin, LLC, a clinical-stage pharmaceutical company focused on developing topical treatments for inflammatory and proliferative skin diseases, today announced positive results from a double-blind, randomized Phase 2a study with MOL4249, a novel compound in development for the treatment of psoriasis. In the study, MOL4249 was shown to be effective in the treatment of mild-to-moderate plaque psoriasis when compared to the vehicle, with no detectable side effects.

"Despite the many treatment options available today, psoriasis continues to be an underserved skin disease with need for improvements in both efficacy and long-term tolerability over available therapies," said Walter Klemp, Chairman and CEO of Moleculin. "The Phase 2 data for MOL4249 are very encouraging and support our plans for continued study in larger numbers of patients."

Study Details

The double-blind, controlled, Phase 2a study involved 16 patients with mild-to-moderate plaque psoriasis. Of these, 10 patients were treated with a topical compound containing MOL4249, while 6 were treated with a control vehicle. Patients applied the treatment twice a day for 28 consecutive days. 50% of patients treated with MOL4249 showed a 50% or better improvement in lesions, versus 17% for the vehicle. In addition, 30% of MOL4249 patients demonstrated a 75% or better improvement in lesions, versus 17% for the vehicle.

Patients and physicians reported no adverse events in the study, suggesting the potential of a topical treatment for psoriasis that is safe for long-term use. MOL4249 is a first-in-class small molecule drug that works by directly inhibiting p-STAT3, a novel target that may contribute to many chronic skin diseases regardless of its activating pathway. Data suggest that this unique mechanism of action may significantly reduce the incidence of side effects, making this compound safe for long-term, chronic use.

About Psoriasis

Psoriasis is a chronic autoimmune skin disease that occurs when the immune system mistakenly speeds up the growth cycle of skin cells. It affects up to 7.5 million Americans and can be difficult to treat because of side effects such as atrophy, or thinning of the skin, with long-term use.

Plaque psoriasis is the most common form of the disease in which people develop itchy skin spots, red patches, and a silvery white buildup of dead skin cells most often appearing on the scalp, lower back, knees, and elbows.

According to a patient survey conducted in the U.S. between 2001 and 2008 by the National Psoriasis Foundation, 33% of patients with mild disease and 60% of patients with moderate-to-severe psoriasis reported that their disease significantly affects their everyday life.

About Moleculin

Moleculin is a clinical-stage pharmaceutical company advancing a new therapeutic approach to inflammatory and proliferative skin diseases, including psoriasis, atopic dermatitis, actinic keratosis, and several skin cancers. The Company's topical compounds are based on the direct inhibition of activated STAT3 (p-STAT3), an important target in the fight against chronic skin diseases. MOL4249, the Company's lead product candidate, is currently being studied in psoriasis. Early clinical studies with this p-STAT3 inhibitor suggest improved efficacy and tolerability for the treatment of mild-to-moderate psoriasis. For more information, visit moleculin.com.


'/>"/>
SOURCE Moleculin, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
2. Allied Healthcare Products Reports Loss On Sales Decline
3. TPI Reports Fiscal Year 2013 Financial Results
4. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
5. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
6. Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
7. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
8. Apollo Medical Holdings Reports Record Fiscal 2014 Second Quarter Results
9. Cyberonics Reports Inducement Equity Award Under NASDAQ Listing Rule 5635(c)(4)
10. Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
11. Omeros Reports Additional Positive Results from OMS824 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 ShangPharma, a ... and cost-effective drug development and discovery services, ... biotechnology industry, announced today the intent for ... will be consolidating the Contract Research Organizations ... Shanghai ChemPartner. These entities include ChemPartner Shanghai, ...
(Date:3/24/2017)... India , March 24, 2017 A ... market has been growing rapidly as the global sales of Adcetris ... the growth in the antibody drug conjugates market is driven by ... of cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly and ... plans to invest $850 million in its U.S. ... across its U.S. enterprise, including research laboratories, manufacturing ... are being driven by demand for Lilly products, ... medicines in development targeting cancer, pain, diabetes and ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/23/2017)... ... 2017 , ... In 2016 the World Health Organization declared the Zika virus ... Zika-related cases in the Americas within the next year. Lyme disease is one of ... skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses are ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating ... communities, 16 more public health departments have been awarded national accreditation through the ... million people into the expanding network of communities across the nation whose health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is ... making a huge impact on businesses and individual consumers alike. Laboratories can maximize ... have a value anywhere from $4 trillion to $11 trillion dollars by the year ...
(Date:3/23/2017)... , ... March 23, 2017 ... ... financial services firm serving the families and businesses of the Norwalk and ... program. Northern Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse ...
Breaking Medicine News(10 mins):